Is it something the drug companies wouldn't already have internally?
Also, profit aside, perhaps open sourcing it would bring the most value to the most people?
I don't know much about the field, but if I was you I'd probably email Professor Eric Grimson at MIT and see if he has any suggestions how your library could be beneficially shared. He seems pretty nice and into this kind of stuff.